[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559978":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":57,"collaborators":23,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":23,"enrollmentInfo":69,"targetDuration":23,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":23,"overallStatus":36,"whyStopped":23,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Intermountain Health Care, Inc.","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Usual Care","ACTIVE_COMPARATOR","Patients will receive usual care for their LDL-C management.",[13],"Other: Usual Care",{"label":15,"type":16,"description":17,"interventionNames":18},"Clinical Pharmacy Team","EXPERIMENTAL","Patients will receive targeted care of their LDL-C through a pharmacist-driven management program.",[19],"Other: Clinical Pharmacy Team",[21,24],{"type":6,"name":15,"description":17,"armGroupLabels":22,"otherNames":23},[15],null,{"type":6,"name":9,"description":25,"armGroupLabels":26,"otherNames":23},"Patient will receive usual care for their LDL-C management.",[9],[28],{"name":29,"role":30,"phone":31,"phoneExt":23,"email":32},"Kirk U Knowlton, MD","CONTACT","801-507-4757","kirk.knowlton@imail.org",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Intermountain Healthcare Hospitals and Clinics","RECRUITING","Salt Lake City","Utah","84107","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-111.89105,40.76078,{"lat":46,"lon":45},[49,51,55],{"name":29,"role":30,"phone":50,"phoneExt":23,"email":32},"801.507.4701",{"name":52,"role":30,"phone":53,"phoneExt":23,"email":54},"Heidi T May, PhD, MSPH","801-507-4700","heidi.may@imail.org",{"name":29,"role":56,"phone":23,"phoneExt":23,"email":23},"PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100559978","a-pragmatic-initiative-for-ldl-c-management-by-a-clinical-pharmacist-led-team-among-atherosclerotic-cardiovascular-disease-patients-100559978",false,"NCT06571162","A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients","A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients (The INCLUDE Trial)","INCLUDE","Inclusion Criteria:\n\n1. Male or female \\>18 years of age\n2. Receive follow-up care with Intermountain Health\n3. Value-based patient (as defined in the EDW)\n4. Documentation of an ASCVD diagnosis, by 1 of the following:\n\n   * Coronary artery disease (Primary inpatient CAD diagnosis during index encounter; Primary inpatient MI diagnosis during index encounter; PCI during index encounter; or CABG during index encounter\n   * Cerebrovascular accident (Primary inpatient ischemic stroke diagnosis during index encounter; Carotid endarterectomy during index encounter; or Carotid stent during index encounter)\n   * Peripheral arterial disease (Bypass or percutaneous intervention during index encounter)\n\nExclusion Criteria:\n\n1. Patient age \\\u003C18 years.\n2. Receipt of or expected receipt of palliative care, expected discharge to hospice, or long-term care facility (i.e., skilled nursing facility).\n3. Pregnant or lactating women","ALL","18 Years",{"count":70,"type":71},400,"ESTIMATED","INTERVENTIONAL",[74],"NA","Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receiving LDL-C management by the pharmacy team at any time. The purpose of this program is to increase the proportion of patients who achieve guideline-based recommendations of LDL-C levels of \\\u003C70 mg\u002FdL by increasing statin and\u002For LLT adherence and LDL-C testing. Data collection as part of the study will continue until the last person randomized has had 1-year of follow-up.",[77],"Atherosclerotic Cardiovascular Disease","2025-05-01",{"date":80,"type":81},"2025-05-06","ACTUAL",{"date":83,"type":81},"2025-01-30",{"date":85,"type":71},"2028-09",{"name":5,"class":6},1]